Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis

Hemophilia B is almost exclusively caused by mutations of the F9 gene and inherited in an X-linked recessive manner. The amino acid residue arginine of factor IX (FIX) with Cpg sequences is a hot spot for mutations, involving CG to TG or CA transitions and causing hemophilia B. Interestingly, for the coding sequence of residue Arg386 of FIX, only the transition CAG to TGA, which causes nonsense mutations, had been identified in a patient with severe hemophilia B, whereas the other type of Cpg transition predicting the missense mutation p.Arg386Gln has been strangely absent from the list of F9 mutations reported in the hemophilia B database. It had been suspected that the particular type of amino acid replacement at this site may lead to conditions other than hemophilia.

In a Chinese patient with deep vein thrombosis (DVT), we identified a F9 mutation at the same site as that in FIX Padua, but differently from this latter, the arginine is changed to a polar amino acid residue glutamine (p.Arg386Gln, HGVS numbering; or p.Arg386Gln, legacy numbering) due to the nucleotide transition c.1151G>A. A coagulation function assay with both the patient’s plasma and recombinant FIX p.Arg386Gln (p.R338Q) showed that the mutation also increased FIX activity. When the FIX with the p.R338Q modification was expressed in vivo after being transferred with self-complementary adeno-associated virus (scAAV) vectors, the deficiency of FIX in a mouse model of hemophilia B was restored, and the bleeding phenotype was significantly ameliorated.

A 13-year-old boy was referred to Ruijin Hospital for consultation regarding recurrent DVT. The patient was well and had no history of other major disorders. The two episodes of DVT had affected both femoral and popliteal veins of his left leg and the diagnosis was confirmed by ultrasound studies. He had no history of left leg trauma and no vascular abnormality was identified in the imaging study. There was no confirmed family history of venous thromboembolism. The patient was being treated with warfarin and this had not been discontinued during the study because of the potential risk of DVT recurrence. The study was approved by the ethics committee of Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine. Written consent was acquired from family members and the patient’s mother on behalf of both parents. Under treatment with warfarin, the activity of three other K-dependent coagulation factors, factors II, VII, and X, was significantly suppressed in the patient; however, his plasma maintained highly elevated FIX activity (FIX:C around 143.1% of normal). In addition, the plasma FIX antigen (FIX:Ag) level was much lower, at approximately 27.5% of normal. The patient’s mother also had relatively higher FIX clotting activity (FIX:C 155.3%) and her FIX:Ag was 75.8% of normal (Table 1).

The coding sequence and flanking regions of the F9 gene were amplified by polymerase chain reaction and directly sequenced. The genes coding for PS, PC, AT III and common genetic thrombotic risk factors, including the factor V Leiden mutation and prothrombin G20210A, were screened. Direct sequencing of the gene revealed a nucleotide substitution c.1151G>A (Figure 1A), which predicted a missense mutation p.Arg338Gln (p.R338Q). The genetic variant was traced back to the patient’s mother (Figure 1B). This pedigree was negative for both factor V Leiden and the prothrombin G20210A mutation. Analysis of the genes for PS, PC, and AT III failed to reveal any pathogenic changes (data not shown).

The F9 cDNA containing the p.R338Q mutation was inserted into the mammalian expression vector pCDNA3.1 and transfected into HEK293T cells using lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) to produce FIX (the methods are described in the Online Supplementary File). The amount and coagulation activity of FIX were determined by enzyme-linked immunosorbsent assay and an activated partial thromboplastin time-based clotting assay. Recombinant FIX was subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis and detected by western blotting using a FIX-specific antibody (PAHFIXS, Haematologic Technologies, Essex Junction, VT, USA). As shown in Figure 1C, the recombinant FIX Shanghai had a similar migration pattern as that of the wild-type FIX and the mutation increased the FIX activity by approximately 5-fold as determined by the ratio of FIX:C to FIX:Ag (Figure 1D), which was similar to the change of FIX activity observed in the patient.

We further investigated the expression and function of FIX p.R338Q in a murine model of hemophilia B using both high and low doses of recombinant adenovirus vectors, with wild-type FIX and FIX p.R338L. The plasmid scAAV-TTR-hFIXcgo (AAV-hFIXcgo) was constructed by cloning codon-optimized human FIX (hFIXcgo) cDNA under control of the human transthyretin (TTR) promoter in a scAAV vector plasmid, and with two inverted terminal repeat sequences of AAV2 flanking the human FIX gene expression cassettes.

Table 1. The coagulation profile of the patient.

|                     | Coagulation factor antigen/activity (%) |
|---------------------|----------------------------------------|
|                     | PT (s) | INR | APTT (s) | FIX:Ag | FIX:C | FVIII:C | FVII:C | FX:C | AT III (%) |
| Patient             | 27.5   | 38.9 | 75.8     | 143.1  | 126.8 | 22.5    | 29.6   | 10.2 | 91        |
| Patient’s mother    | 9.3    | 0.81 | 29.1     | 155.3  | 159.9 | 93.6    | 118.5  | 96.5 | 97        |

PT: prothrombin time; INR: international normalized ratio; APTT: activated partial thromboplastin time; AT III: antithrombin III; F: factor; Ag: antigen; C: coagulation factor activity; Normal reference range for APTT: 25.1–39.5 s; PT: 9.9–15 s; coagulation factor activity: 50–150%; AT III activity: 84.6–120.2%.
The plasmids scAAV-TTR-hFIXcOR338Q (AAV-hFIXcOR338Q) and scAAV-TTR-hFIXcOR338L (AAV-hFIXcOR338L) were obtained by site-directed mutagenesis of the plasmid AAV-hFIXco at p.R338L and p.R338Q, respectively. Recombinant AAV type 8 (rAAV8) vectors were generated by triple plasmid transfection (methods provided in the Online Supplementary File). Two vector doses of approximately $5 \times 10^{10}$ and $4 \times 10^{11}$ rAAV8 viral genomes (vg), which were equivalent to $2 \times 10^{5}$ or $1.6 \times 10^{7}$ vg/kg in a clinical setting, were diluted in 200 μL of phosphate-buffered saline and injected into 4- to 8-week old hemophilia B mice via the tail vein (n=5 mice per group). FIX:Ag and FIX:C were determined in the mice by enzyme-linked immunosorbent assay and an activated partial thromboplastin-based assay, using pooled normal human plasma as the standard. Twenty-four weeks after injection of AAV vectors packed with either of the FIX species, the FIX:C of FIX p.R338Q and p.R338L was three to five times higher than that of the wild-type FIX at most of the time points examined ($P<0.05$) (Figure 2A, D, G, J). The expression (FIX:Ag) of FIX p.R338Q was similar to that of FIX p.R338L, but lower than that of wild-type FIX, particularly at a low dose (Figure 2B, E, H, K). The in vivo expression study validated that the FIX p.R338Q mutant had intrinsically higher clotting activity than wild-type FIX, with 4- to 5-fold higher FIX-specific activity as determined in mice given either high or low doses of the vector (Figure 2C, F and I, L, respectively). The FIX clotting activity enhancement brought by p.R338Q was on average 20% less than that brought by p.R338L.

The amino acid residue Arg338 has a profound effect on the procoagulant activity of FIX and laboratory studies on the artificial mutation FIX p.Arg338Ala showed that replacement of the positively charged arginine by a hydrophobic alanine could increase the FIX activity by 2-3-fold. In a pedigree with thrombophilia in Padua (Italy), replacement of the positively charged amino acid residue Arg338 with a nonpolar amino acid residue, leucine, led to an approximately 8-fold increase in FIX clotting activity.

In our Chinese patient with thrombophilia, we found the long-sought CpG transition-related mutation c.1151G>A (p.Arg338Gln), which we designated FIX Shanghai. Although there have been contradictory reports on the mutation’s impact on clotting activity, pre-

![Figure 1. F9 gene analysis and determination of FIX Shanghai clotting function.](image)
viously determined by using an artificially made mutant, the early onset and recurrences of DVT in our patient carrying FIX Shanghai evidently substantiate the effect of this mutation on upregulating coagulation activity. The mutation greatly increased the clotting activity of the patient’s plasma FIX, as did the recombinant mutant expressed in HEK293 cells, although on average 20% less than the FIX Padua mutation. Consistent with findings in humans, hemophilia B mice into which the FIX Shanghai mutant was transferred by AAV vectors also presented with increased FIX activity \textit{in vivo}.

The dosage of AAV vectors is directly related to the safety and efficacy of a gene therapy for hemophilia B, and it would be ideal to achieve high FIX expression with lower doses of AAV vectors. Discovery of the FIX Padua mutation promoted the development of gene therapy. Continued on the next page.
In vivo evaluation of FIX Shanghai following delivery by adeno-associated virus vectors into hemophilic B mice. Evaluation of codon-optimized hFIXco, hFIXco-R338L, and hFIXco-R338Q by recombinant adeno-associated virus (rAAV) delivery in hemophilia B (HB) mice. Each 4- to 8-week old HB mouse was injected with a total amount of 5x10^{10} vector genomes (low dose) or 4x10^{11} vector genomes (high dose) via the tail vein (n=5 in each group). Phosphate-buffered saline (PBS) was injected as a negative control (n=3). FIX clotting activity and protein quantity were measured by the activated partial thromboplastin time (APTT) (A, G) and enzyme-linked immunosorbent assay (ELISA) (B, H) using plasma samples collected at the indicated times after rAAV administration. A pooled human plasma was used as the normal standard. Specific activities (C, I) were calculated as APTT/ELISA at the corresponding points. Data are mean ± standard error of mean. Statistical analysis was done with analysis of variance testing using GraphPad Prism 6 (Graphpad Software, Inc. La Jolla, CA, USA). Representative results for A, B, C, G, H and I, at weeks 0, 2, 6 and 24 are shown in D, E, F, J, K and L, respectively. P values less than 0.05 were considered statistically significant (ns: >0.05; *P≤0.05; **P≤0.01; ***P≤0.001).

Figure 2.
With high FIX clotting activity, the AAV vector carrying the F9 Padua variant achieved therapeutic levels of FIX in patients without toxic side effects.1 With a similar effect on FIX activity as FIX Padua, the AAV-delivered FIX Shanghai in a hemophilia B mouse model yielded sustained FIX expression, and the FIX clotting activity achieved in the mice by FIX Shanghai was significantly better than that of wild-type FIX and similar to that of FIX Padua. The adoption of a naturally occurring hypercoagulative FIX mutation, FIX Shanghai, is thus an attractive approach for the development of a gene therapy regimen for hemophilia B with high efficacy and fewer safety concerns.

In conclusion, the new FIX variant identified in the current study, FIX Shanghai (FIX p.Arg338Gln), greatly increased FIX clotting activity and potentiated the risk of thrombosis. Before use in clinical trials, the potential toxicity of this variant should be studied further in animals. However, its high activity also makes it an ideal candidate for the development of novel gene therapy regimens for hemophilia B.

Wenman Wu,1,2 Lin Xiao,3 Xi Wu,1 Xiaoling Xie,1 Ping Li,1 Changning Chen,1 Zhaoyue Zheng,1 Jiangang Ai,1 C. Alexander Valencia,1,2 Birong Dong,3 Qiu Lan Ding,4 Biao Dong5 and Xuefeng Wang2

1Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Faculty of Medical Laboratory Science, Ruijin Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China; 3State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and National Collaborative Innovation Center, Chengdu, Sichuan, China; 4Department of Laboratory Medicine, Jiangxi Provincial People’s Hospital, Nanchang, China; 5National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China; 6Lake Erie College of Osteopathic Medicine, Erie, PA, USA and 7Apentomics, Inc., Sterling, VA, USA

WW and LX contributed equally as co-first authors.

Correspondence: XUEFENG WANG - wxf65@shsmu.edu.cn
QIU LAN DING - qiuilan_ding@shsmu.edu.cn
BIAO DONG - biaodong@sci.edu.cn
doi:10.3324/haematol.2019.216713

Disclosures: no conflicts of interests to disclose.

Contributions: WW designed experiments, analyzed data, and wrote the paper; LX execute animal work, analyzed data and wrote the paper; PL and ZZ prepared AAV vectors; XX, CC, JA expressed recombinant protein and performed function assay; AV wrote the paper; BD planned the experiments of AAV vectors; XV performed the clotting function assays and FIX antigen determination of patient; XW and QD established the diagnosis of the patients, oversighted experiments and wrote the paper; BD planned and conducted the experiments of AAV vectors and wrote the paper.

Funding: this work was supported by NSFC 81470130, WW; NSFC 81570145, XV; NSFC 81570144, QD; NSFC 81471792, BD.

References

1. Goodve AC. Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost. 2015;13(7):1184-1195.
2. Koeberl DD, Bottema CD, Buestedde JM, Sommer SS. Functionally important regions of the factor IX gene have a low rate of polymorphism and a high rate of mutation in the dinucleotide CpG. Am J Hum Genet. 1989;45(3):448-457.
3. Vitkup D, Sander C, Church GM. The amino-acid mutational spectrum of human genetic disease. Genome Biol. 2003;4(11):R72.
4. Green PM, Montandon AJ, Bentley DR, Liung R, Nilsson IM, Giannelli F. The incidence and distribution of CpG→TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res. 1990;18(11):3227-3231.
5. Ludwig M, Schwaab R, Egel A, et al. Identification of a single nucleotide C→T transition and five different deletions in patients with severe hemophilia B. Am J Hum Genet. 1989;45(1):115-122.
6. Gostout B, Viellhaber E, Ketterling RP, et al. Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-Caucasians. Hum Mol Genet. 1993;2(5):293-298.
7. Bottema CDK, Ketterling RP, Viellhaber E, et al. The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. Hum Genet. 1993;91(5):496-503.
8. Nathwani AC, Gray JT, Ng CY, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2006;107(7):2653-2661.
9. Chang J, Jin J, Lollar P, et al. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem. 1998;273(20):12089-12094.
10. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671-1675.
11. Monahan FE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther. 2015;26(2):69-81.
12. Manno CS, Arruda VR, Pierce GE, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347.
13. Lozier JN. Factor IX Padua: them that have, give. Blood. 2012;120(28):4452-4453.
14. George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215-2227.